Blood transfusion as regulator of the immune response

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 1, 2006, Pages 89-96

  Van De Watering, Leo M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allograft survival; Blood transfusion; HLA; Immunoregulation; Leukocytes; Transfusion reaction

Indexed keywords

ALLOIMMUNIZATION; ANTIGEN RECOGNITION; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CANCER RECURRENCE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOREGULATION; POSTOPERATIVE INFECTION; REVIEW; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 33644551575     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090198     Document Type: Review

References (96)

1. Landsteiner K: Über Agglutinationserscheinungen normalen menschlichen Blutes. Wien Klin Wochenschr 1901;14:1132.
2. Gantt CL: Red blood cells for cancer patients. Lancet 1981;ii:363.
3. Joint statement on acquired immune deficiency syndrome (AIDS) related to transfusion. Transfusion 1983;23:87-8.
4. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O: Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;ii:662-665.
5. Opelz G, Sengar DP, Mickey MR, Terasaki PI: Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253-9.
6. Persijn GG, Cohen B, Lansbergen Q, van Rood JJ: Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979;28:396-401.
7. Vamvakas EC, Blajchman MA: Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001;97:1180-95.
8. Blajchman MA: Transfusion immunomodulation or TRIM: What does it mean clinically? Hematology 2005;10(suppl 1):208-214.
9. Chaplin H Jr: Packed red blood cells. N Engl J Med 1969;281:364-7.
10. Diepenhorst P, Engelfriet CP: Removal of leukocytes from whole blood and erythrocyte suspensions by filtration through cotton wool. V. Results after transfusion of 1,820 units of filtered erythrocytes. Vox Sang 1975;29:15-22.
11. Ibojie J, Greiss MA, Urbaniak SJ: Limited efficacy of universal leucodepletion in reducing the incidence of febrile nonhaemolytic reactions in red cell transfusions. Transfus Med 2002;12:181-185.
12. Fast LD: Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective alloantigen-presenting cells. Blood 2000;96:1144-1149.
13. Novotny VM, van Doorn R, Witvliet MD, Claas FH, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995;85:1736-1741.
14. Scornik JC, Ireland JE, Howard RJ, Fennell RS3, Pfaff WW: Role of regular and leukocyte-free blood transfusions in the generation of broad sensitization. Transplantation 1984;38:594-598.
15. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-205.
16. van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A: HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003;43:765-771.
17. Liu Z, Braunstein NS, Suciu-Foca N: T cell recognition of allopeptides in context of syngeneic MHC. J Immunol 1992;148:35-40.
18. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P: Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004;44:1774-1789.
19. Popovsky MA: Transfusion-related acute lung injury. Curr Opin Hematol 2000;7:402-7.
20. Aoun E, Shamseddine A, Chehal A, Obeid M, Taher A: Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center. Transfusion 2003;43:1672-1676.
21. Spector D: Transfusion-associated graft-versus-host disease: an overview and two case reports. Oncol Nurs Forum 1995;22:97-101.
22. Ohto H, Anderson KC: Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996;10:31-43.
23. Arsura EL, Bertelle A, Minkowitz S, Cunningham JN Jr, Grob D: Transfusion-associated-graft-vs-host disease in a presumed immunocompetent patient. Arch Intern Med 1988;148:1941-1944.
24. Kruskall MS, Lee TH, Assmann SF, Laycock M, Kalish LA, Lederman MM, Busch MP: Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001;98:272-9.
25. Stainsby D, Russell J, Cohen H, Lilleyman J: Reducing adverse events in blood transfusion. Br J Haematol 2005;131:8-12.
26. Ness PM, Shirey RS, Thoman SK, Buck SA: The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688-693.
27. Redman M, Regan F, Contreras M: A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996;71:216-220.
28. Fluit CR, Kunst VA, Drenthe-Schonk AM: Incidence of red cell antibodies after multiple blood transfusion. Transfusion 1990;30:532-535.
29. Ramsey G, Larson P: Loss of red cell alloantibodies over time. Transfusion 1988;28:162-165.
30. Schonewille H, Haak HL, van Zijl AM: RBC antibody persistence. Transfusion 2000;40:1127-1131.
31. Schonewille H, Haak HL, van Zijl AM: Alloimmnnization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999;39:763-71.
32. Issitt PD, Anstee DJ: Applied Blood Group Serology, 4th ed. Durham, NC, Montgomery Scientific Publications, 1998.
33. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C: Red cell alloantibodies in patients with thalassemia. Vox Sang 1990;58:50-55.
34. Murphy MF, Waters AH: Platelet transfusions: the problem of refractoriness. Blood Rev 1990;4:16-24.
35. Novotny VM: Platelet transfusion refractoriness - prevention and therapeutical approaches. Transfus Clin Biol 1995;2:47-49.
36. Vamvakas EC: Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 1998;12:258-270.
37. Schnaidt M, Northoff H, Wernet D: Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996; 6:111-114.
38. Mueller-Eckhardt C, Kiefel V, Kroll H, Mueller-Eckhardt G: HLA-DRw6, a new immune response marker for immunization against the platelet alloantigen Bra. Vox Sang 1989;57:90-91.
39. Lee EJ, Schiffer CA: ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989;29:384-389.
40. Sandler SG, Mallory D, Malamut D, Eckrich R: IgA anaphylactic transfusion reactions. Transfus Med Rev 1995;9:1-8.
41. Wilhelm D, Kluter H, Klouche M, Kirchner H: Impact of allergy screening for blood donors: relationship to nonhemolytic transfusion reactions. Vox Sang 1995;69:217-221.
42. Lambin P, Le Pennec PY, Hauptmann G, Desaint O, Habibi B, Salmon C: Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. Vox Sang 1984;47:242-249.
43. Ohio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F: Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999;93:1770-7.
44. Horimi T, Terasaki PI, Chia D, Sasaki N: Factors influencing the paradoxical effect of transfusions on kidney transplants. Transplantation 1983;35:320-323.
45. Blumberg N, Heal JM, Murphy P, Agarwal MM, Chuang C: Association between transfusion of whole blood and recurrence of cancer. Br Med J (Clin Res Ed) 1986;293:530-533.
46. Magee CC, Sayegh MH: Peptide-mediated immunosuppression. Curr Opin Immunol 1997;9:669-675.
47. Marsh J, Donnan PT, Hamer-Hodges DW: Association between transfusion with plasma and the recurrence of colorectal carcinoma. Br J Surg 1990;77:623-626.
48. Nielsen HJ: Detrimental effects of perioperative blood transfusion. Br J Surg 1995;82:582-7.
49. Mynster T, Nielsen HJ: The impact of storage time of transfused blood on postoperative infectious complications in rectal cancer surgery. Danish RANX05 Colorectal Cancer Study Group. Scand J Gastroenterol 2000;35:212-7.
50. Vamvakas EC, Blajchman MA: Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfus Med Rev 2000;14:23-33.
51. Gafter U, Kalechman Y, Sredni B: Blood transfusion enhances production of T-helper-2 cytokines and transforming growth factor beta in humans. Clin Sci (Lond) 1996;91:519-523.
52. Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Strohlein MA, Tarabichi A, Faist E, Jauch KW, Schildberg FW: Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery. Shock 1997;8:402-8.
53. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A: Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998;97:562-568.
54. Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, Descoeudres C, Ruder H, Wujciak T, Schwarz V: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997;63:964-967.
55. Lagaaij EL, Hennemann IP, Ruigrok M, de Haan MW, Persijn GG, Termijtelen A, Hendricks GF, Weimar W, Claas FH, van Rood JJ: Effect of one-HLA-DR-antigen- matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321:701-5.
56. Opelz G, Mickey MR, Terasaki PI: Identification of unresponsive kidney-transplant recipients. Lancet 1972;i:868-871.
57. Mincheff MS, Meryman HT, Kapoor V, Alsop P, Wotzel M: Blood transfusion and immunomodulation: a possible mechanism. Vox Sang 1993;65:18-24.
58. Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F: Fas, Fas ligand,and transfusion immunomodulation. Transfusion 2001;41:416-418.
59. Claas FH, de Koster HS, Lagaaij EL, van Rood JJ: A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol 1993;1:134-138.
60. Waanders MM, Roelen DL, Brand A, Claas FH: The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev 2005;19:281-287.
61. Claas FH, Roelen DL, van Rood JJ, Brand A: Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol 2001;8:315-317.
62. Roelen D, Brand A, Claas FH: Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells? Transplantation 2004;77:S26-S28.
63. Tartter PI, Driefuss RM, Malon AM, Heimann TM, Aufses AH: Relationship of postoperative septic complications and blood transfusions in patients with Crohn's disease. Am J Surg 1988;155:43-8.
64. Braga M, Vignali A, Radaelli G, Gianotti L, Di Carlo V: Association between perioperative blood transfusion and postoperative infection in patients having elective operations for gastrointestinal cancer. Eur J Surg 1992;158:531-536.
65. Heiss MM, Mempel W, Jauch KW, Delanoff C, Mayer G, Mempel M, Eissner HJ, Schildberg FW: Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993;342:1328-33.
66. Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, Pahlplatz P, Eeftinck SM, Wobbes T, de Vries JE: Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-578.
67. Koval KJ, Rosenberg AD, Zuckerman JD, Aharonoff GB, Skovron ML, Bernstein RL, Su E, Chakka M: Does blood transfusion increase the risk of infection after hip fracture? J Orthop Trauma 1997;11:260-5;discussion 265-6.
68. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR: Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002;42:1127-1134.
69. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP: Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003;54:908-914.
70. Vamvakas EC: Possible mechanisms of allogeneic blood transfusion- associated postoperative infection. Transfus Med Rev 2002;16:144-160.
71. Jensen LS, Andersen AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, Mortensen J, Moller-Nielsen C, Hanberg-Sorensen F, Hokland M: Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79:513-516.
72. Blajchman MA: Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: do we have the answers yet? Transfusion 1997;37:121-5.
73. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N: Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348:841-5.
74. Tartter PI, Mohandas K, Azar P, Endres J, Kaplan J, Spivack M: Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998;176:462-6.
75. Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J: Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomized study. Int J Colorectal Dis 2001;16:147-53.
76. van Hilten JA, van de Watering LM, van Bockel JH, van de Velde CJ, Kievit J, Brand R, van den Hout WB, Geelkerken RH, Roumen RM, Wesselink RM, Koopman-van Gemert AW, Koning J, Brand A: Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. BMJ 2004;328:1281.
77. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, Brand A: Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004;109:2755-2760.
78. Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I, vanWalraven C, Devine D, Sher GD: Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289:1941-9.
79. Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP: A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42:1114-1122.
80. Llewelyn CA, Taylor RS, Todd AA, Stevens W, Murphy MF, Williamson LM: The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004;44:489-500.
81. van de Watering L: What has universal leucodepletion given us: evidence from clinical trials? Vox Sang 2004;87(suppl 2):139-142.
82. Vamvakas EC: Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996;36:175-186.
83. Amato AC, Pescatori M: Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum 1998;41:570-585.
84. McAlister FA, Clark HD, Wells PS, Laupacis A: Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg 1998;85:171-178.
85. van de Watering LM, Brand A, Houbiers JG, Klein Kranenbarg WM, Hermans J, van de Velde C: Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001;88:267-272.
86. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
87. Maeta M, Shimizu N, Oka A, Kondo A, Yamashiro H, Tsujitani S, Ikegchi M, Kaibara N: Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. J Surg Oncol 1994;55:149-53.
88. Penn I, Starzl TE: Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation 1972;14:407-17.
89. Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000;23:101-13.
90. Waymack JP, Chance WT: Effect of blood transfusions on immune function: IV. Effect on tumor growth. J Surg Oncol 1988;39:159-64.
91. Shirwadkar S, Blajchman MA, Frame B, Singal DP: Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice. J Cancer Res Clin Oncol 1992;118:176-180.
92. Goodarzi MO, Lee TH, Pallavicini MG, Donegan EA, Busch MP: Unusual kinetics of white cell clearance in transfused mice. Transfusion 1995;35:145-9.
93. Lee TH, Reed W, Mangawang-Montalvo L, Watson J, Busch MP: Donor WBCs can persist and transiently mediate immunologic function in a murine transfusion model: effects of irradiation, storage, and histocompatibility. Transfusion 2001;41:637-42.
94. Hewitt HB: A critical examination of the foundations of immunotherapy for cancer. Clin Radiol 1979;30:361-9.
95. Natali PG, Bigotti A, Cavaliere R, Nicotra MR, Ferrone S: Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst 1984;73:13-24.
96. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ, Moller P: Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986;37:179-84.